Comorbidities and side effects of the imunomodulatory treatment in multiple sclerosis
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
794 5
Ultima descărcare din IBN:
2021-03-26 14:57
Căutarea după subiecte
similare conform CZU
616.8-004-097-08 (1)
Neurologie. Neuropatologie. Sistem nervos (963)
SM ISO690:2012
GROSU, C., MITROPOULOU, E., POPESCU, C., ALEXA, Daniel. Comorbidities and side effects of the imunomodulatory treatment in multiple sclerosis. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2015, nr. 2(47), pp. 166-172. ISSN 1857-0011.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale
Numărul 2(47) / 2015 / ISSN 1857-0011

Comorbidities and side effects of the imunomodulatory treatment in multiple sclerosis
CZU: 616.8-004-097-08

Pag. 166-172

Grosu C.1, Mitropoulou E.2, Popescu C.1, Alexa Daniel1
 
1 University of Medicine and Pharmacy “Grigore T. Popa”, Iasi,
2 Marine Hospital Athens
 
Disponibil în IBN: 3 februarie 2016


Rezumat

Multiple sclerosis is a demyelinating, neurodegenerative disease of the central nervous system, that affects the young adult and is associated with a high degree of disability. Physical and mental comorbidity and adverse health behaviors are common in patients with MS. Comorbidities and health behaviors are associated with adverse outcomes in MS and should be considered in the assessment and management of patients with MS. We have studied a group of 150 MS patients treated with immunomodulators inside the Romanian national MS treatment programme. The patients we analysed corresponded to the available literature in matters or number, age and sex. We searched for associated pathology and side effects of the treatment. After selecting and statistically analyzing the data we concluded that dyslipidemia was the most common comorbidity, followed by hyperglicemia and vertebral hernia. The presence or not of a comorbidity before the treatment does not relate to the EDSS score (p<0.05). Thus the presence or not of an associated pathology during 7 years of immunomodulatory treatment does not affect the patient’s EDSS score and disability. The most frequent side effects in our study were anemia, thrombocytopenia, raised liver enzymes, dyslipidemia, lymphocitopenia and neurtropenia. The anemia was a mild one, with no signifi cantly decrease haemoglobin and hematocrit levels. The same is observed with the liver enzymes, while the increase in SGOT and SGPT values are 40% increase in comparison with the maximum accepted normal value. Summarizing the results of the side effects, it seems that as time of treatment rises, the side effects free patients decrease in actual number.

Cuvinte-cheie
multiple sclerosis, comorbidities, side effects